Top 5 Managed Healthcare Stocks To Own For 2014

With shares of J.C. Penney (NYSE:JCP) trading around $6, is JCP an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

J.C. Penney is a retailer operating more than 1,000 department stores in just about every state in the United States and Puerto Rico. Its business consists of selling merchandise and services to consumers through its department stores and website. It sells family apparel and footwear, accessories, fine and fashion jewelry, beauty products through Sephora, and home furnishings. The company has not done too well in recent years, but it is doing what it can to be a top provider of apparel and related products.

J.C. Penney�� decision to close 33 underperforming stores and to trim 2,000 positions won�� have much significant long-term impact on the retailer�� business model, one analyst says.�Rick Snyder, senior retail analyst at Maxim Group, says the announcement — which J.C. Penney says will result in $65 million in annual savings — only changes his forecasting models slightly. Mr. Snyder has a hold rating on J.C. Penney and doesn�� have a price target on the stock.�Ultimately, he described the announcement as ��uch ado about very little.��/p>

Top Consumer Stocks To Own Right Now: Numerex Corp.(NMRX)

Numerex Corp. provides business services, technology, and products used in the development and support of machine-to-machine solutions for the enterprise and government markets worldwide. The company offers Numerex DNA that includes hardware and smart devices, cellular and satellite network services, and software applications that are delivered through Numerex FAST (Foundation Application Software Technology). Its customers subscribe to device management, network, and application services through hosted platforms. The company distributes its products through value added resellers, system integrators, and original equipment manufacturers. It serves security, energy and utilities, healthcare, financial services, government, transportation, and supply chain markets. The company was founded in 1988 and is headquartered in Atlanta, Georgia.

Advisors' Opinion:

• [By John Udovich]

  Small cap machine-to-machine (M2M) stock Elecsys Corp (NASDAQ: ESYS) jumped 8.99% yesterday and is up 254% over the past year, meaning it might be time to take a closer look at the stock and its performance verses other small cap M2M stocks like Digi International Inc (NASDAQ: DGII), Numerex Corp (NASDAQ: NMRX) and Sierra Wireless, Inc (NASDAQ: SWIR). First of all though, I should mention that machine-to-machine (M2M) broadly refers to technologies that allow both wireless and wired systems to communicate with other devices of the same type and this can be through any type of technology ranging from instruments to networks to applications that create connections between devices.

• [By Seth Jayson]

  Margins matter. The more Numerex (Nasdaq: NMRX  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Numerex's competitive position could be.

Top 5 Managed Healthcare Stocks To Own For 2014: Peregrine Pharmaceuticals Inc.(PPHM)

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment of cancer and viral infections. Its products under development include bavituximab, a phosphatidylserine-targeting antibody, which is in Phase II trials for the treatment of front-line and second-line non-small cell lung cancer (NSCLC), and pancreatic cancer; and Cotara, a DNA/histone-targeting antibody that is in Phase II trial for the treatment of recurrent glioblastoma multiforme. The company is also developing bavituximab in combination with ribavirin, which is in Phase II clinical trial for the treatment of patients with genotype-1 hepatitis C virus infection. In addition, it has investigator-sponsored trial programs that evaluate bavituximab for the treatment of patients with liver cancer, second-line castration resistant prostate cancer, HER-2 negative metastatic breast cancer, and locally advanced or metasta tic NSCLC. Further, the company, through its wholly-owned subsidiary, Avid Bioservices, Inc., provides integrated current Good Manufacturing Practices (cGMP) commercial and clinical manufacturing services in the United States, including contract manufacturing of antibodies, recombinant proteins, and enzymes; cell culture development; process development; and testing of biologics for biopharmaceutical and biotechnology companies under cGMP. It has licensing agreements with the University of Texas Southwestern Medical Center; Merck KGaA; SuperGen, Inc.; and Affitech A/S. Peregrine Pharmaceuticals, Inc. intends to sell its products in the United States and internationally in collaboration with marketing partners or through a direct sales force. The company was founded in 1981 and is based in Tustin, California.

Advisors' Opinion:

• [By Sean Williams]

  What: Shares of Peregrine Pharmaceuticals (NASDAQ: PPHM  ) , a biopharmaceutical company developing monoclonal antibodies to treat cancer, jumped as much as 19% after the company reported final data on its mid-stage second-line non-small cell lung cancer drug, Bavituximab, at the annual American Society of Clinical Oncology meeting.

• [By Tom Bemis]

  Few major companies are reporting after Monday�� bell. Results are expected from Destiny Media Technologies (DSNY) �, Stanley Furniture Co. (STLY) � and Peregrine Pharmaceuticals. (PPHM) �.

• [By Rick Munarriz]

  I went out on a limb last week, and now it's time to see how that decision played out.

  I predicted that Noodles & Co. (NASDAQ: NDLS  ) would close lower on the week. After seeing the fresh IPO more than double and command a $1.3 billion market cap far sooner than its fundamentals should allow, I figured it would be in for reality check. A negative Barron's piece kicked off the week in the seemingly appropriate bearish tone, but the shares did start to claw their way back later in the week. It wasn't enough. The shares fell 3% on the week. I was right. I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average. (DJINDICES: ^DJI  ) . This has been a tricky call lately, so how did it play out this time? Well, the market closed nicely higher this week. The Nasdaq moved 3.5% higher, and the Dow managed to close just 2.2% higher. I was right. My final call was for Peregrine Pharmaceuticals (NASDAQ: PPHM  ) to beat Wall Street's income estimates in its latest quarter. The upstart biotech tackling cancer through monoclonal antibodies has been posting blowout quarterly results over the past year, and I was banking on seeing the trend continue. Analysts were looking for a loss of $0.06 a share during the quarter, and it came through with exactly that. It wasn't a beat, though, so I was wrong.

  Two out of three? I can do better than that.

• [By Sean Williams]

  Also gaining double digits on the week was the highly embattled Peregrine Pharmaceuticals (NASDAQ: PPHM  ) which rallied after the FDA approved its late-stage trial design for its second-line non-small-cell lung cancer immunotherapy, Bavituximab. While trial design approvals are rarely big news, it is in this case because mid-stage results for Bavituximab have been all over the place. At first Bavituximab demonstrated a better than doubling in progression-free survival followed weeks later by management's insistence that investors were not to trust the data. A few months later, following a review, we were told to trust the data again. This filing helps relieve some of the confusion surrounding Peregrine's mid-stage results, and hopefully its phase 3 study will be black-and-white obvious as to whether Bavituximab provides a statistically significant benefit.

Top 5 Managed Healthcare Stocks To Own For 2014: Jones Lang LaSalle Incorporated (JLL)

Jones Lang LaSalle Incorporated, a financial and professional services firm, provides integrated real estate and investment management services to owner, occupier, investor, developer clients worldwide. Its real estate services comprise agency leasing, investment management, tenant representation, real estate investment banking/merchant banking, property management, corporate finance, facilities management/outsourcing, hotel/hospitality advisory, project and development management/construction, energy and sustainability services, valuations, value recovery and receivership services, consulting, logistics and supply chain management, and capital markets. The company offers these services to real estate owners, occupiers, investors, and developers for various property types, including offices, multi-family residential and military housing, hotels, critical environments and data centers, industrial properties, sports facilities, retail properties, cultural facilities, healthc are and laboratory facilities, transportation centers, government facilities, and educational facilities. It also provides a range of real estate investment products and services in the public and private capital markets, as well as indirect public investments primarily in publicly traded real estate investment trusts and other real estate equities. Jones Lang LaSalle Incorporated was founded in 1997 and is based in Chicago, Illinois.

Advisors' Opinion:

• [By Hilary Kramer]

   

  2. Real Estate Investment Trusts (REITs) The REIT is another alternative vehicle that's gone mainstream in recent years. Hundreds of broad-based and specialized real estate companies and ETFs are available, and after a correction a few months ago, many are on the cheap side. Like any other alternative, this should be a seasoning for your portfolio and not the sauce itself. For most retail investors, a stake in an indexed fund like the SPDR Dow Jones REIT (NYSE: RWR) should be more than adequate, or look into the companies that provide services to the REIT industry like HFF (NYSE: HF) and Jones Lang LaSalle (NYSE: JLL).

   

• [By Ben Levisohn]

  The healthcare REIT is busy trying to convince investors that there’s nothing behind the move other than the fact that they wanted a new leadership style when the place Jones Lang LaSalle’s�(JLL) Lauralee Martin at the helm. Cowen’s James Sullivan explains why the move continues to shake up investors:

• [By John Udovich]

  Midcaps CBRE Group Inc (NYSE: CBG) and Jones Lang LaSalle Inc (NYSE: JLL) are probably the better known real estate services stocks with the latter surging 12.36% yesterday on impressive earnings, but small cap stocks Kennedy-Wilson Holdings Inc (NYSE: KW) and FirstService Corporation (NASDAQ: FSRV) are also important real estate services providers that you may have overlooked. After all, real estate services stocks like the following would offer exposure to real estate by being invested in property as well as generating revenue from transactions, property management and other services: ��

Top 5 Managed Healthcare Stocks To Own For 2014: Guggenheim CurrencyShares Japanese Yen Trust (FXY)

Guggenheim CurrencyShares Japanese Yen Trust, formerly CurrencyShares Japanese Yen Trust, is a grantor trust. The Trust issues shares (the Shares) in blocks of 50,000 (a Basket) in exchange for deposits of Japanese Yen and distributes Japanese Yen in connection with the redemption of Baskets. The investment objective of the Trust is for the Shares to reflect the price of Japanese Yen plus accrued interest, if any, less the expenses of the Trust�� operations. The Trust holds Japanese Yen and, from time to time, issues Baskets in exchange for deposits of Japanese Yen and distributes Japanese Yen in connection with redemptions of Baskets. The Sponsor of the Trust is Guggenheim Specialized Products, LLC, a Delaware limited liability company.

The Bank of New York Mellon, a banking corporation with trust powers organized under the laws of the State of New York, serves as the Trustee. The Shares are backed by the assets of the Trust, which does not hold or use derivative products.

Advisors' Opinion:

• [By Matthew McCall]

  The Rydex CurrencyShares Japanese Yen ETF (NYSE: FXY) has since fallen by nearly 30 percent since hitting a high during the fourth quarter of 2011.

• [By Ben Levisohn]

  Fears–and hopes–for rising rates were apparent everywhere. Charles Schwab (SCHW), a beneficiary of higher rates, rose 3.2% to $27.58.�Newmont Mining (NEM) dropped 3.1% to $24.50 because who needs gold when rates are heading higher? The iShares MSCI Emerging Markets ETF (EEM) fell 2.1% to $38.57 because we all know higher rates in the US are bad news for emerging markets.�The 10-year Treasury yield rose to 2.77% and the CurrencyShares Japanese Yen Trust (FXY) declined 1.1% to $95.22.

• [By Richard Cox]

  In ETFs, this translates to substantially bearish moves in PowerShares DB US Dollar Index Bullish (UUP) and highly bullish moves in theCurrencyShares Japanese Yen Trust (FXY). The BoJ left policy unchanged, with no stated plans to alter the 60 trillion Yen ($611 billion) in annual injections to the country's monetary base. Most analysts were expecting the BoJ would approve loan operations that extend to two years (or longer), and the results put renewed focus on the 10-year Japanese treasury note. Since the BoJ announced its historic stimulus plan in April, the 10-year note has risen from its all-time lows at 0.315% to highs of 1%. The main ideological thrust of the BoJ must be kept in perspective, however, as there is still clear long-term concern for the prospects of the country's export companies and pronounced efforts in place to bring consumer inflation levels back toward normal ranges.